Alcobra Company Profile (NASDAQ:ADHD)

About Alcobra (NASDAQ:ADHD)

Alcobra logoAlcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine. MDX consists of a single bi-layer oral tablet, which includes both a rapid onset release metadoxine formulation and a slow release metadoxine formulation together providing the desired dual release profile. The new extended-release formulation prolongs the human plasma levels of metadoxine for up to 12 hours, which results in enhanced efficacy benefits. ADAIR is an oral, semi-solid, liquid-filled, hard gelatin capsule of an abuse-deterrent IR formulation of dextroamphetamine sulfate, which is manufactured as 10 mg capsules.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ADHD
  • CUSIP: N/A
  • Web: www.alcobra-pharma.com
Capitalization:
  • Market Cap: $31.7 million
  • Outstanding Shares: 27,562,000
Average Prices:
  • 50 Day Moving Avg: $1.07
  • 200 Day Moving Avg: $1.11
  • 52 Week Range: $0.83 - $2.58
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.73
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.71 per share
  • Price / Book: 0.72
Profitability:
  • EBITDA: ($21,410,000.00)
  • Return on Equity: -45.34%
  • Return on Assets: -42.69%
Debt:
  • Current Ratio: 25.53%
  • Quick Ratio: 25.53%
Misc:
  • Average Volume: 287,844 shs.
  • Beta: 1.49
  • Short Ratio: 13.65
 

Frequently Asked Questions for Alcobra (NASDAQ:ADHD)

What is Alcobra's stock symbol?

Alcobra trades on the NASDAQ under the ticker symbol "ADHD."

How were Alcobra's earnings last quarter?

Alcobra Ltd. (NASDAQ:ADHD) posted its quarterly earnings data on Friday, August, 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. View Alcobra's Earnings History.

When will Alcobra make its next earnings announcement?

Alcobra is scheduled to release their next quarterly earnings announcement on Tuesday, November, 21st 2017. View Earnings Estimates for Alcobra.

Where is Alcobra's stock going? Where will Alcobra's stock price be in 2017?

8 analysts have issued twelve-month price objectives for Alcobra's stock. Their predictions range from $1.00 to $2.00. On average, they anticipate Alcobra's stock price to reach $1.61 in the next year. View Analyst Ratings for Alcobra.

What are analysts saying about Alcobra stock?

Here are some recent quotes from research analysts about Alcobra stock:

  • 1. According to Zacks Investment Research, "Alcobra Ltd. is a biopharmaceutical company. It focuses on the development and commercialization of drugs to treat attention deficit hyperactivity disorder. Alcobra Ltd. is headquartered in Tel Aviv, Israel. " (10/11/2017)
  • 2. Cantor Fitzgerald analysts commented, "Development of new drugs carries a high failure rate, either because the drug in question fails to show efficacy or significant safety issues arise during the clinical trial process. In addition, regulatory authorities such as the Food & Drug Administration (FDA) may delay the approval process or reject Alcobra’s clinical findings." (4/13/2017)
  • 3. Piper Jaffray Companies analysts commented, "We're not particularly surprised by this outcome as the truncated dataset greatly reduced the power of this trial to demonstrate a significant impact on the CAARS. Alcobra now plans to use its ~$50M in cash to execute on a new business plan, the details of which should become available during 1Q17. We expect this could involve development of MDX in ex-US markets, or of new candidates from the company's internal pipeline or in-licensing efforts. Given the prolonged timelines to next clinical data and first revenues, as well as increased execution risk we see for this team, we are reducing our PT from $3 to $1.50, or roughly equivalent to cash/share. In advance of more details on a plan forward, we reiterate N." (1/17/2017)

Who are some of Alcobra's key competitors?

Who are Alcobra's key executives?

Alcobra's management team includes the folowing people:

  • Yaron Daniely, Chairman of the Board
  • David C. Baker, Interim Chief Executive Officer and Chief Commercial Officer
  • Tomer Berkovitz, Chief Financial Officer
  • Hagit Marchaim Ph.D., Senior Vice President - Regulatory Affairs
  • Hanna Ron, Senior Vice President of Chemistry, Manufacturing and Control
  • Oded Edri, Vice President - Finance
  • Johanna Schumann, Vice President - Preclinical Development
  • Jonathan Rubin M.D., Chief Medical Officer
  • Daniel E. Geffken CPA, Director
  • Aharon Schwartz, Director

How do I buy Alcobra stock?

Shares of Alcobra can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alcobra's stock price today?

One share of Alcobra stock can currently be purchased for approximately $1.23.


MarketBeat Community Rating for Alcobra (NASDAQ ADHD)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  187 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  356
MarketBeat's community ratings are surveys of what our community members think about Alcobra and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alcobra (NASDAQ:ADHD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $1.61 (30.66% upside)
Consensus Price Target History for Alcobra (NASDAQ:ADHD)
Price Target History for Alcobra (NASDAQ:ADHD)
Analysts' Ratings History for Alcobra (NASDAQ:ADHD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/9/2017WBB SecuritiesUpgradeHold -> Buy$2.00N/AView Rating Details
9/29/2017Roth CapitalDowngradeBuy -> Neutral$4.00 -> $1.00LowView Rating Details
6/12/2017Jefferies Group LLCReiterated RatingHold$1.25LowView Rating Details
4/13/2017Cantor FitzgeraldReiterated RatingHold$1.00LowView Rating Details
1/17/2017Stifel NicolausSet Price TargetHold$2.00N/AView Rating Details
1/17/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldN/AView Rating Details
1/17/2017Piper Jaffray CompaniesSet Price TargetHold$3.00 -> $2.00N/AView Rating Details
10/28/2016Barclays PLCDowngradeEqual Weight -> Underweight$3.00 -> $2.00N/AView Rating Details
9/1/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuyN/AView Rating Details
6/7/2016Canaccord GenuityInitiated CoverageBuyN/AView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Alcobra (NASDAQ:ADHD)
Earnings by Quarter for Alcobra (NASDAQ:ADHD)
Earnings History by Quarter for Alcobra (NASDAQ ADHD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/15/2017($0.11)N/AView Earnings Details
8/11/20176/30/2017($0.15)($0.13)ViewN/AView Earnings Details
5/30/20173/31/2017($0.15)($0.13)ViewN/AView Earnings Details
2/15/201712/31/2016($0.26)($0.22)ViewListenView Earnings Details
11/15/2016Q316($0.27)($0.28)$4.30 million$7.90 millionViewN/AView Earnings Details
8/30/2016Q216($0.22)($0.21)ViewListenView Earnings Details
5/16/2016Q116($0.22)($0.18)ViewListenView Earnings Details
2/17/2016Q415($0.24)($0.20)ViewListenView Earnings Details
11/12/2015Q315($0.31)($0.20)ViewN/AView Earnings Details
8/13/2015Q215($0.30)($0.24)ViewListenView Earnings Details
5/6/2015Q1 2015($0.31)($0.26)ViewN/AView Earnings Details
2/12/2015Q4($0.57)($0.50)ViewN/AView Earnings Details
11/17/2014Q3 14($0.61)($0.77)ViewN/AView Earnings Details
8/11/2014Q2($0.58)($0.57)ViewListenView Earnings Details
2/13/2014Q413($0.35)($0.45)ViewN/AView Earnings Details
11/7/2013Q313($0.28)ViewN/AView Earnings Details
8/6/2013Q213($0.06)($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alcobra (NASDAQ:ADHD)
2017 EPS Consensus Estimate: ($0.71)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.25)($0.15)($0.20)
Q2 20172($0.23)($0.13)($0.18)
Q3 20172($0.18)($0.14)($0.16)
Q4 20172($0.19)($0.15)($0.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alcobra (NASDAQ:ADHD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Alcobra (NASDAQ:ADHD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Alcobra (NASDAQ:ADHD)
Latest Headlines for Alcobra (NASDAQ:ADHD)
Source:
DateHeadline
seekingalpha.com logoArcturus Merges With Alcobra - Seeking Alpha
seekingalpha.com - October 15 at 3:22 PM
americanbankingnews.com logoAlcobra Ltd. (ADHD) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 11 at 8:28 PM
americanbankingnews.com logoAlcobra Ltd. (ADHD) Upgraded to "Buy" at WBB Securities
www.americanbankingnews.com - October 9 at 10:50 PM
americanbankingnews.com logoAlcobra Ltd. (ADHD) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - October 7 at 4:52 AM
finance.yahoo.com logoArcturus Therapeutics, Inc. to Present at the Chardan Gene Therapy Conference
finance.yahoo.com - October 6 at 3:49 PM
finance.yahoo.com logoShould You Be Concerned About Alcobra Ltd’s (ADHD) Risks?
finance.yahoo.com - October 6 at 1:25 AM
americanbankingnews.com logoAlcobra Ltd. (ADHD) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - October 4 at 9:14 PM
americanbankingnews.com logoRoth Capital Downgrades Alcobra Ltd. (ADHD) to Neutral
www.americanbankingnews.com - September 29 at 10:56 AM
streetinsider.com logoAlcobra Ltd. (ADHD) Reports Merger with Arcturus Therapeutics Inc. - StreetInsider.com
www.streetinsider.com - September 29 at 9:56 AM
streetinsider.com logoAlcobra Ltd. (ADHD) Reports Merger with Arcturus Therapeutics Inc.
www.streetinsider.com - September 28 at 3:56 PM
feeds.benzinga.com logoAlcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge
feeds.benzinga.com - September 27 at 7:33 PM
seekingalpha.com logoAlcobra Is A Net-Net That Could Sell Itself - Seeking Alpha
seekingalpha.com - September 20 at 8:28 PM
americanbankingnews.com logoAlcobra Ltd. (ADHD) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 12 at 4:40 AM
americanbankingnews.com logoAlcobra Ltd. (ADHD) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 18 at 4:42 AM
americanbankingnews.com logoAlcobra Ltd. (NASDAQ:ADHD) Releases Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - August 12 at 10:56 AM
finance.yahoo.com logoAlcobra Announces Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 11 at 4:00 PM
finance.yahoo.com logoAlcobra reports 2Q loss
finance.yahoo.com - August 11 at 4:00 PM
americanbankingnews.com logoAlcobra Ltd. (ADHD) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 9 at 7:00 AM
zacks.com logoNew Strong Buy Stocks for July 26th
www.zacks.com - July 26 at 8:28 PM
nasdaq.com logoNew Strong Buy Stocks for July 26th - Nasdaq
www.nasdaq.com - July 26 at 3:27 PM
americanbankingnews.com logoAlcobra Ltd. (ADHD) Expected to Post Earnings of -$0.13 Per Share
www.americanbankingnews.com - July 25 at 12:26 AM
americanbankingnews.com logoAlcobra Ltd. (ADHD) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - July 24 at 10:54 AM
finance.yahoo.com logoBioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session
finance.yahoo.com - July 21 at 4:45 PM
finance.yahoo.com logoBioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session
finance.yahoo.com - July 21 at 4:45 PM
finance.yahoo.com logoNew Strong Buy Stocks for July 20th
finance.yahoo.com - July 20 at 3:50 PM
streetinsider.com logoAlcobra Ltd. (ADHD) to Review of Strategic Alternatives
www.streetinsider.com - June 24 at 1:55 AM
streetinsider.com logoAlcobra Ltd. (ADHD) to Review of Strategic Alternatives - StreetInsider.com
www.streetinsider.com - June 23 at 8:54 PM
News IconUPDATE 1-Shire wins U.S. approval for long-acting ADHD drug
www.businessinsider.com - June 22 at 12:53 PM
nasdaq.com logoShire wins US approval for long-acting ADHD drug - Nasdaq
www.nasdaq.com - June 21 at 3:49 PM
nasdaq.com logoShire's long-acting ADHD drug wins US approval - Nasdaq
www.nasdaq.com - June 20 at 8:52 PM
streetinsider.com logoAlcobra Ltd. (ADHD) Enters Cooperation Agreement with Brosh ... - StreetInsider.com
www.streetinsider.com - June 13 at 5:40 AM
streetinsider.com logoAlcobra Ltd. (ADHD) Gains on Rumors of Bid from Regenera - StreetInsider.com
www.streetinsider.com - June 9 at 3:25 PM
nasdaq.com logoSwiss biotech NLS Pharma's ADHD drug succeeds in mid-stage ... - Nasdaq
www.nasdaq.com - May 31 at 3:19 PM
globenewswire.com logoAlcobra Announces First Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - May 30 at 10:07 AM
streetinsider.com logoAlcobra (ADHD) CEO to Step Down, Remain on Board
www.streetinsider.com - May 16 at 8:20 PM
streetinsider.com logoAlcobra (ADHD) CEO to Step Down, Remain on Board - StreetInsider.com
www.streetinsider.com - May 15 at 3:20 PM
globenewswire.com logoAlcobra Announces Leadership Update - GlobeNewswire (press release)
globenewswire.com - May 15 at 8:09 AM
streetinsider.com logoAlcobra (ADHD) And Brosh Group Reach Agreement to Cancel Extraordinary General Meeting
www.streetinsider.com - May 7 at 3:20 PM
streetinsider.com logoAlcobra (ADHD) And Brosh Group Reach Agreement to Cancel Extraordinary General Meeting - StreetInsider.com
www.streetinsider.com - May 5 at 3:20 PM
globenewswire.com logoAlcobra Mails Proxy Materials for Extraordinary General Meeting of Shareholders - GlobeNewswire (press release)
globenewswire.com - April 24 at 3:21 PM
streetinsider.com logoAlcobra Ltd. (ADHD) Rejects Brosh Capital's Request to Hold Extraordinary General Meeting
www.streetinsider.com - April 7 at 3:21 PM
streetinsider.com logoAlcobra Ltd. (ADHD) Rejects Brosh Capital's Request to Hold ... - StreetInsider.com
www.streetinsider.com - April 7 at 6:30 AM
bizjournals.com logoResearch Reports Initiation on Biotech Stocks -- Alcobra, Cerus, 22nd Century, and Moleculin Biotech
www.bizjournals.com - April 3 at 3:32 PM
streetinsider.com logoBrosh Capital Requests Extraordinary General Meeting at Alcobra (ADHD), Seeks to Remove Board in Full - StreetInsider.com
www.streetinsider.com - March 18 at 3:18 PM
globenewswire.com logoAlcobra to Host Investor Forum and Webcast on March 28 in New ... - GlobeNewswire (press release)
globenewswire.com - March 1 at 3:20 PM
globenewswire.com logoIMPORTANT ALCOBRA LTD. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a ... - GlobeNewswire (press release)
globenewswire.com - February 25 at 3:17 PM
us.rd.yahoo.com logoIMPORTANT ALCOBRA LTD. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the Southern District of New York on behalf of purchasers of Alcobra Ltd.
us.rd.yahoo.com - February 24 at 8:20 PM
globenewswire.com logoSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class ... - GlobeNewswire (press release)
globenewswire.com - February 24 at 9:47 AM
prnewswire.com logoLifshitz & Miller LLP Files Class Action Lawsuit against Alcobra, Ltd. - PR Newswire (press release)
www.prnewswire.com - February 17 at 6:47 PM
seekingalpha.com logoAlcobra (ADHD) Presents At 19th Annual BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 16 at 3:20 PM

Social

Chart

Alcobra (ADHD) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.